I.BjrkqvistM
Taking them together increases the risk of side effects, particularly cardiovascular strain, and should only be done under strict medical monitoring
In the UK, several GLP-1 receptor agonists are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA), each with specific indications: semaglutide (Ozempic for type 2 diabetes, Wegovy for weight management), dulaglutide (Trulicity for type 2 diabetes), and liraglutide (Victoza for type 2 diabetes, Saxenda for weight management)
Its estimated that around 400,000 individuals worldwide have this syndrome, including 20,000 people in the United States
Moreover, the success of GLP-1 drugs serves as a testament to the importance of continued investment in metabolic research